Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Dedifferentiated central chondrosarcoma.

Eric L Staals1, Patrizia Bacchini, Franco Bertoni

  • 1Fifth Orthopedic Division, Istituto Ortopedico Rizzoli, Bologna, Italy.

Cancer
|May 13, 2006
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

A modified Delphi consensus on tenosynovial giant cell tumour and giant cell tumour of bone : a report from the Birmingham Orthopaedic Oncology Meeting (BOOM).

The bone & joint journal·2026
Same author

A modified Delphi consensus on periprosthetic infection in orthopaedic oncology : a report from the Birmingham Orthopaedic Oncology Meeting (BOOM).

The bone & joint journal·2025
Same author

What is debridement, antibiotics, and implant retention in orthopaedic oncology? : a global cross-sectional survey of surgeons' practices and opinions.

Bone & joint open·2025
Same author

Cartilage Repair and Symptom Relief After Autologous Microfragmented Adipose-Derived Mesenchymal Stem Cell Therapy in Hip Osteoarthritis: A Case Report with Histological Correlation.

Current stem cell research & therapy·2025
Same author

Identifying consensus and areas for future research in chondrosarcoma : a report from the Birmingham Orthopaedic Oncology Meeting.

The bone & joint journal·2025
Same author

Biological Sample Collection to Advance Research and Treatment: A Fight Osteosarcoma Through European Research and Euro Ewing Consortium Statement.

Clinical cancer research : an official journal of the American Association for Cancer Research·2024
Same journal

Toward exercise as standard care for older cancer survivors.

Cancer·2026
Same journal

Maintenance therapy in gynecologic malignancies: Current and future state.

Cancer·2026
Same journal

Long-term outcomes of evolving treatment regimens in Ewing sarcoma survivors diagnosed 1970-1999: A report from the Childhood Cancer Survivor Study.

Cancer·2026
Same journal

Large-scale osteosarcoma sequencing reveals age-associated genomic architectures.

Cancer·2026
Same journal

EZH2 inhibitor tazemetostat voluntarily withdrawn from market.

Cancer·2026
Same journal

Nivolumab and chemotherapy combination approved for previously untreated Hodgkin lymphoma.

Cancer·2026
See all related articles

Prognosis for dedifferentiated central chondrosarcoma is poor. Factors like metastatic disease, malignant fibrous histiocytoma, and a large dedifferentiated component predict worse outcomes, with no clear benefit from chemotherapy.

Area of Science:

  • Orthopedic Oncology
  • Skeletal Tumors
  • Sarcoma Research

Background:

  • Dedifferentiation of central chondrosarcoma carries a historically poor prognosis.
  • Limited data exists on prognostic factors for this rare condition.

Purpose of the Study:

  • To identify prognostic factors influencing outcomes in patients with dedifferentiated central chondrosarcoma.
  • To analyze clinical, radiographic, and histologic features and treatments.

Main Methods:

  • Retrospective review of 123 patients with dedifferentiated central chondrosarcoma.
  • Analysis of clinical, radiographic, and histologic data.
  • Evaluation of treatment modalities and survival rates.

Main Results:

Related Experiment Videos

  • Common locations include femur, pelvis, and humerus.
  • A soft tissue mass and bimorphic pattern were frequent radiographic findings.
  • Osteosarcoma was the most common dedifferentiated component; 2-year and 5-year survival rates were 34% and 24% respectively.

Conclusions:

  • Metastatic disease at diagnosis, dedifferentiation as malignant fibrous histiocytoma, and a high percentage of the dedifferentiated component are associated with poorer outcomes.
  • Adjuvant chemotherapy did not demonstrate a statistically significant beneficial effect.